Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias.

ABSTRACT:

Study objective

To estimate the incidence of 10 common cancers among patients treated with antimuscarinic medications for overactive bladder (AMOABs).

Design

Retrospective cohort study.

Data source

United Kingdom's Clinical Practice Research Datalink.

Patients

A total of 119,912 adults with no previous cancer diagnosis who were new users of AMOABs-darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, or trospium-between January 2004 and December 2012.

Measurements and main results

Sex-specific incidence rates per 1000 person-years and 95% confidence intervals (CIs) were estimated for each study cancer (bladder, breast, colorectal, lung, melanoma, non-Hodgkin lymphoma, pancreatic, prostate, renal, and uterine cancer) overall and stratified by t

SUBMITTER: Kaye JA 

PROVIDER: S-EPMC5518180 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature